EMEA-001990-PIP01-16-M05 - paediatric investigation plan | European Medicines Agency (EMA)
Skip to main content
EMEA-001990-PIP01-16-M05 - paediatric investigation plan
fenfluramine hydrochloride
PIPHuman
Key facts
Invented name
Fintepla
Active Substance
fenfluramine hydrochloride
Therapeutic area
Neurology
Decision number
P/0390/2022
PIP number
EMEA-001990-PIP01-16-M05
Pharmaceutical form(s)
Oral solution
Condition(s) / indication(s)
Treatment of Dravet syndrome
Route(s) of administration
Oral use
Gastric use
Contact for public enquiries
UCB Pharma SA
Email: ucbcares.uk@ucb.com Tel. +44 175777100
Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Decision
P/0390/2022: EMA decision of 9 September 2022 on the acceptance of a modification of an agreed paediatric investigation plan for fenfluramine (hydrochloride) (Fintepla), (EMEA-001990-PIP01-16-M05)